三重激动剂 comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2026-08-01. Where a claim depends on a specific study, the study is described rather than over-claimed.
Each receptor contributes a different physiological effect. Activation of the GLP-1 receptor slows gastric emptying and reduces appetite signaling in the brain. GIP receptor activity influences insulin secretion and lipid handling, while glucagon receptor stimulation raises energy use and fat oxidation. Combining these pathways is intended to produce weight loss beyond what single- or dual-receptor agonists achieve. Researchers attribute the observed potency to simultaneous engagement of all three targets, though the exact contribution of each receptor to overall effect remains under investigation.
Clinical development has advanced through phase 2 trials in adults with obesity and type 2 diabetes. Reported phase 2 results described substantial average weight reduction over roughly forty-eight weeks of weekly dosing. A phase 3 program is ongoing to confirm efficacy and assess long-term safety. Because the compound has not received regulatory approval, it is not available as a prescription product. Public discussion of retatrutide often conflates trial findings with marketed status, an important distinction when interpreting coverage of the topic.
Retatrutide is an investigational peptide studied for obesity and type 2 diabetes. It is a single synthetic molecule designed to activate three metabolic receptors simultaneously. The compound belongs to the incretin mimetic family, a group of peptides that imitate gut hormones involved in appetite and glucose control. Its research code is LY3437943, and it remains under clinical study rather than cleared for routine medical use.
Acting as a triple agonist, the molecule binds the GLP-1, GIP, and glucagon receptors. GLP-1 activity slows gastric emptying and dampens appetite, while GIP signaling contributes to insulin sensitivity and fat metabolism. Glucagon receptor engagement raises energy expenditure and encourages fat breakdown, although it can also elevate blood glucose. Combining three pathways is intended to yield larger weight reduction than single or dual agonists, and researchers continue to examine how the balance among them shapes tolerability.
Clinical studies have reported notable reductions in body weight among participants. Early trials measured safety and explored several dose levels, and later studies tracked body-weight change over months of treatment. Investigators also monitor effects on glycemic markers, liver fat, and blood lipids. Because the compound is still in development, questions about long-term safety, cardiovascular outcomes, and durability after treatment ends remain open.
| Property | Value | Notes |
|---|---|---|
| Molecule class | Synthetic peptide | Engineered triple receptor agonist |
| Molecular weight | Approximately 4731 Da | Reported value; depends on form |
| Receptor targets | GLP-1, GIP, glucagon | Simultaneous activation |
| Development code | LY3437943 | Internal company designation |
| Current status | Investigational | No approved indication reported |
Pharmacologically the compound activates three receptors: GLP-1, GIP, and glucagon. GLP-1 and GIP signaling contribute to glucose-dependent insulin release, delayed gastric emptying, and reduced appetite, while glucagon receptor activation is associated with increased energy expenditure and hepatic fat oxidation. The single-molecule design is intended to keep these activities in one peptide rather than combining separate agents. Relative activity at each receptor differs, and the balance between them is a central question in interpretation. The glucagon component is partly offset by incretin-mediated insulin secretion, an interaction that remains incompletely characterized.
Development has progressed from single- and multiple-ascending-dose studies in healthy volunteers into larger randomized trials in adults with obesity, type 2 diabetes, and fatty liver disease. Early reports describe dose-dependent reductions in body weight and improvements in glycemic markers over treatment periods of several months. Whether the glucagon arm adds tolerability cost without added benefit is still debated. Long-term cardiovascular outcomes, effects after treatment stops, and performance in older or comorbid populations are open questions rather than settled findings. Approval status may change, so the current investigational label should be confirmed against regulatory sources.
与仅靶向单一受体的同类药物相比，瑞他鲁肽增加胰高血糖素受体成分，理论上可提高能量消耗并改变脂肪分布。临床中观察到的体重变化是否主要来自该额外机制，目前尚无定论。胃肠道反应是该类药物常见不良事件，试验中通过剂量递增和监测进行管理。停药后体重反弹、个体差异和长期耐受性仍需更多数据。
瑞他鲁肽是一种在研合成肽，同时作用于胰高血糖素样肽-1、葡萄糖依赖性促胰岛素多肽和胰高血糖素受体。该分子属于多受体激动剂类别，尚未获得任何监管机构的上市批准。当前临床开发主要针对肥胖和2型糖尿病，研究代号为LY3437943。已确立的信息包括受体靶点和部分中期试验结果；最终疗效、长期安全性和适用人群仍属开放问题。
== Plasminogen Activator Role in Breast Cancer == Plasminogen activator inhibitor-1 not only functions as an inhibitor, but other roles of PAI-1 could suggest it could contribute to cancer. The other roles of PAI-1 include, cell de-adhesion, cell proliferation, apoptosis, and cell signaling. These roles could suggest that PAI-1 expression in the tumor microenvironment enhances tumor cell progression. Urokinase cleaves the zymogen plasminogen into serine protease plasmin. The elevated levels of uPA are an indicator of cancer which could be found in the carcinoma of the breast. Plasmin can activate matrix metalloproteases (MMP's) in the extracellular matrix (ECM). MMP activation contributes to tumor cell invasion and metastasis by degradation of ECM components.
== Release == Library of Ruina was initially released for Windows via Steam's early access program on May 15, 2020, before being fully released for Windows and Xbox One on August 10, 2021. Versions for Nintendo Switch and PlayStation 4 were made available by publisher Arc System Works on April 25, 2024.
The exterior of an individual segment is a thin cuticle over the skin, commonly pigmented red to brown, which has specialized cells that secrete mucus over the cuticle to keep the body moist and ease movement through the soil. Under the skin is a layer of nerve tissue, and two layers of muscles—a thin outer layer of circular muscle, and a much thicker inner layer of longitudinal muscles. Interior to the muscle layer is a fluid-filled chamber called a coelom that by its pressurization provides structure to the worm's boneless body. The segments are separated from each other by septa (the plural of "septum") which are perforated transverse walls, allowing the coelomic fluid to pass between segments. A pair of structures called nephrostomes are located at the back of each septum; a nephric tubule leads from each nephrostome through the septum and into the following segment. This tubule then leads to the main body fluid filtering organ, the nephridium or metanephridium, which removes metabolic waste from the coelomic fluid and expels it through pores called nephridiopores on the worm's sides; usually, two nephridia (sometimes more) are found in most segments. At the centre of a worm is the digestive tract, which runs straight through from mouth to anus without coiling, and is flanked above and below by blood vessels (the dorsal blood vessel and the ventral blood vessel as well as a subneural blood vessel) and the ventral nerve cord, and is surrounded in each segment by a pair of pallial blood vessels that connect the dorsal to the subneural blood vessels.
== Development == Series writer Marc Laidlaw initially conceived of Black Mesa, and brainstormed numerous potential names before arriving on the final one, including "Black Butte Missile Base", "Diablo Plains", and "Diablo Mesa". In Half-Life 2: Raising the Bar, he professed that he was glad his final choice was Black Mesa Research Facility, rather than "Black Butte". Black Mesa's themes of science and horror were partially inspired by "The Borderland", an episode of The Outer Limits that focused on a team of scientists who manipulated magnetic fields to enter the fourth dimension. The monorail sequence that introduces the player to the Black Mesa facility was initially intended as a tech demo. Laidlaw stated that when a programmer implemented a new type of game object called "func_tracktrain", which allowed trains to branch onto different tracks, as well as bank and pivot into turns, he decided to incorporate a train into the game's story. The path of the monorail itself is made up of six different map files without individual loading screens, adding hallways as transition areas to give the illusion of level streaming. The disaster sequence in the test chamber was created in a single weekend by developers John Guthrie and Kelly Bailey, who worked for 48 hours straight without sleep, ultimately exciting everyone in the office when they discovered and played it the following Monday.
Vladimir Khatskelevich Khavinson (Russian: Владимир Хацкелевич Хавинсон; 27 November 1946 – 6 January 2024) was a Russian gerontologist and professor who was Treasurer of the European region of the International Association of Gerontology and Geriatrics; Main gerontologist of the Health Committee of the Government of Saint Petersburg, Russia; Director of the Saint Petersburg Institute of Bioregulation and Gerontology; Vice-president of Gerontological Society of the Russian Academy of Sciences; Head of the Chair of Gerontology and Geriatrics of the North-Western State Medical University in Saint Petersburg; Colonel of medical service (USSR, Russia). Vladimir Khavinson is known for the discovery, experimental and clinical studies of new classes of peptide bioregulators as well as for the development of bioregulating peptide therapy. He was engaged in studying of the role of peptides in regulation of the mechanisms of ageing. His main field of actions was design, pre-clinical and clinical studies of new peptide geroprotectors. A 40-year-long investigation resulted in a multitude of methods of application of peptide bioregulators to slow down the process of ageing and increase human life span. Six peptide-based pharmaceuticals and 64 peptide food supplements have been introduced into clinical practice by Khavinson. Patenting endogenous peptides is not a common practice as they are considered a "natural product". He authored 196 patents (Russian and international) as well as of 775 scientific publications.
Sources: en.wikipedia.org
==== Quorum sensing ==== Quorum sensing is a method that depends on detecting cell or molecule densities to trigger specific responses. As cell density increases, signalling molecule concentrations also increase, eventually reaching a threshold that activates a response. This mechanism is useful to lower functioning costs for bacteria, as this allows high-energy responses to only occur when they are triggered as necessary by the signalling molecule. Known signalling molecules observed in algicidal responses include acyl-homoserine lactones (AHLs), quinolones, and diketopiperazines. Taxa such as Pseudomonas sp., Pseudoalteromonas sp., Vibrio sp., and Alteromonas sp. all demonstrate algicidal activity linked to quorum sensing mechanisms.
=== Ha === Fritz Haber (1868–1934), German chemist, 1918 Nobel Prize in Chemistry, father of the Haber process Dorothy Hahn (1876–1950), early American organic chemist and ultraviolet spectroscopist Otto Hahn (1879–1968), German chemist, discoverer of nuclear fission, 1944 Nobel Prize in Chemistry, father of nuclear chemistry Sossina M. Haile (born 1966), American chemist notable for developing the first solid acid fuel cells Naomi Halas (PhD 1987), American biochemist focusing on nanoshells and nanophotonics John Burdon Sanderson Haldane (1892–1962), British and Indian biochemist, geneticist and evolutionary biologist Charles Martin Hall (1863–1914), American chemist known for the Hall-Héroult process for inexpensive production of aluminum Frances Mary Hamer (1894–1980), British chemist who specialized in photographic sensitization compounds George S. Hammond (1921–2005), American chemist, famous for Hammond's postulate as part of the general theory of the transition state in chemical reactions Arthur Harden (1865–1940), English biochemist, Nobel Prize in Chemistry in 1929 for work on the fermentation of sugar and fermentative enzymes Elizabeth Hardy (1915–2008), Canadian-American chemist who discovered the Cope rearrangement of dienes Anna J.
The outermost layer of the gastrointestinal wall consists of several layers of connective tissue and is either of serosa (below the diaphragm) or adventitia above the diaphragm. Regions of the gastrointestinal tract within the peritoneum (called Intraperitoneal) are covered with serosa. This structure consists of connective tissue covered by a simple squamous epithelium, called the mesothelium, which reduces frictional forces during digestive movements. The intraperitoneal regions include most of the stomach, first part of the duodenum, all of the small intestine, caecum and appendix, transverse colon, sigmoid colon and rectum. In these sections of the gut there is clear boundary between the gut and the surrounding tissue. These parts of the tract have a mesentery. Regions of the gastrointestinal tract behind the peritoneum (called retroperitoneal) are covered with adventitia. They blend into the surrounding tissue and are fixed in position (for example, the retroperitoneal section of the duodenum usually passes through the transpyloric plane). The retroperitoneal regions include the oral cavity, esophagus, pylorus of the stomach, distal duodenum, ascending colon, descending colon and anal canal.
== Structure == The crystal structure of AGAT was determined by Humm, Fritsche, Steinbacher, and Huber of the Max Planck Institute of Biochemistry in Martinsried, Germany in 1997. X-ray examinations of the structure reveal a novel symmetry with fivefold pseudosymmetry of beta beta alphabeta modules. The overall structure of the molecule resembles a basket with handles. The active site lies at the bottom of a long, narrow channel and includes a Cys-His-Asp catalytic triad. The intermediate structure involves the amidino group temporarily covalently bonding to the Cys residue on the catalytic triad, while the His residue takes part in general acid/base catalysis, meaning it acts as a proton donator/receiver itself.
Sources: en.wikipedia.org
Fistulectomy is a surgical procedure where a surgeon completely removes a fistula, an abnormal tract (i.e. tube) that connects two hollow spaces of the body. In comparison to other procedural options of treating fistulae such as fistulotomies, where a fistula is cut open (i.e. unroofed) but not completely removed, and seton placement, where a rubber band seton is passed through the tract and left post-operation as a means to allow drainage of the fistula, fistulectomies are considered to be a more radical approach. The total removal of a fistula may damage nearby structures in the process. In practice, fistulectomies are primarily performed by colorectal surgeons to treat anorectal fistulous tracts, as fistulas commonly emerge in the anorectal region. In this case, fistulectomies may compromise a patient's anal sphincter, as the removal process may necessitate the surgeon to cut through the muscle. As a result, this may lead to complications such as incontinence. For this reason, fistulectomies are no longer considered the "gold standard".
=== Generic names === Pseudoephedrine is the generic name of the drug and its INNTooltip International Nonproprietary Name and BANTooltip British Approved Name, while pseudoéphédrine is its DCFTooltip Dénomination Commune Française and pseudoefedrina is its DCITTooltip Denominazione Comune Italiana. Pseudoephedrine hydrochloride is its USANTooltip United States Adopted Name and BANMTooltip British Approved Name in the case of the hydrochloride salt; pseudoephedrine sulfate is its USAN in the case of the sulfate salt; pseudoephedrine polistirex its USAN in the case of the polistirex form; and d-isoephedrine sulfate is its JANTooltip Japanese Accepted Name in the case of the sulfate salt. Pseudoephedrine is also known as Ψ-ephedrine and isoephedrine.
Calculations using a quantum-tunneling model predict the existence of several heavier isotopes of oganesson with alpha-decay half-lives close to 1 ms. Theoretical calculations done on the synthetic pathways for, and the half-life of, other isotopes have shown that some could be slightly more stable than the synthesized isotope 294Og, most likely 293Og, 295Og, 296Og, 297Og, 298Og, 300Og and 302Og (the last reaching the N = 184 shell closure). Of these, 297Og might provide the best chances for obtaining longer-lived nuclei, and thus might become the focus of future work with this element. Some isotopes with many more neutrons, such as some located around 313Og, could also provide longer-lived nuclei. The isotopes from 291Og to 295Og might be produced as daughters of element 120 isotopes that can be reached in the reactions 249–251Cf+50Ti, 245Cm+48Ca, and 248Cm+48Ca. In a quantum-tunneling model, the alpha decay half-life of 294Og was predicted to be 0.66+0.23−0.18 ms with the experimental Q-value published in 2004. Calculation with theoretical Q-values from the macroscopic-microscopic model of Muntian–Hofman–Patyk–Sobiczewski gives somewhat lower but comparable results.
Timothy Jostling & Donna Roberts (2001). "The Beef Hormone Dispute Between The United States and the EU". In Gerald C. Nelson (ed.). Genetically Modified Organisms in Agriculture: Economics and Politics. Academic Press. pp. 291–294. ISBN 0-12-515422-4. William A Kerr & Jill E Hobbs (February 2002). "The North American-European Union Dispute Over Beef Produced Using Growth Hormones: A Major Test for the New International Trade Regime". The World Economy. 25 (2): 283–296. doi:10.1111/1467-9701.00431. S2CID 154707486. SSRN 309524. Michael Balter (28 May 1999). "Scientific cross-claims fly in continuing beef war". Science. 284 (5419): 1453–1455. doi:10.1126/science.284.5419.1453. PMID 10383320. S2CID 5519384.
=== Ethnic groups === According to the 2021 census, ethnically the Bromley town ward was 70.1% White, 54.0% were White British, White Irish 1.7%, Roma 0.4% and 14.0% Other White. Asians were 12.8%, Black were 7.4%, mixed 6.7% and other were 3.0%.
Sources: en.wikipedia.org
Retatrutide is an investigational peptide that activates the GLP-1, GIP, and glucagon receptors at the same time. It is being studied for obesity and type 2 diabetes and has not been approved for clinical use. The internal code LY3437943 refers to the same molecule.
Most approved incretin therapies target one or two receptors, while retatrutide engages three. The addition of glucagon receptor activity is intended to raise energy expenditure. This broader mechanism is the subject of ongoing research rather than established practice.
No regulatory agency has approved retatrutide for any indication as of available public information. Development remains in later-stage trials. Availability claims found online should be treated as unverified.
It is a synthetic peptide classified as a triple receptor agonist. It engages the GLP-1, GIP, and glucagon receptors at once. It is investigated for metabolic and weight-related conditions rather than approved for general use.